This guideline covers managing acute painful sickle cell episodes in children, young people and adults who present at hospital, from presentation until when they are discharged.
This annual, global campaign, held each year on June 19th, aims to raise public awareness and spread knowledge of sickle cell disease (SCD) which affects millions of people worldwide.
The UK National Institute for Health and Care Excellence (NICE) has not recommended use of Adakveo (crizanlizumab), from Novartis, for use in preventing recurrent sickle cell crises (vaso-occlusive crises) in people aged 16 or over with sickle cell disease.
The FDA has granted regular approval to hydroxyurea (Siklos) from Addmedica, to reduce the frequency of painful crises and the...
bluebird bio, Inc. announced the FDA has approved Lyfgenia (pronounced as ‘lif-JEN-ee-uh’) (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).
Global Blood Therapeutics, Inc.announced that the FDA has granted accelerated approval for Oxbryta (voxelotor) tablets for the treatment of sickle...
Novartis announced that the FDA has granted crizanlizumab (SEG 101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs)...
Emmaus Life Sciences, Inc., announced it has submitted a New Drug Application (NDA) to the FDA requesting U.S. marketing approval...
bluebird bio, Inc. announced the submission of its Biologics License Application (BLA) to the FDA for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events (VOEs)
First Drug Designed Specifically for Sickle Cell Disease Shows Benefits in Adolescents, according to data presented at The American Society of Hematology (ASH) Annual Meeting.